Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sagent Pharmaceuticals Inc Raises Low End Of Prior FY 2013 Revenue Guidance; Raises FY 2013 Net Income Guidance


Tuesday, 6 Aug 2013 07:00am EDT 

Sagent Pharmaceuticals Inc announced that for fiscal 2013, it expects net revenue to be in the range of $230 to $250 million driven by 10 to 15 product launches and net income to between $18 million and $28 million, a increase from the previous range of $5 million to $15 million. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $246 million and net income of $10.44 million for fiscal 2013. 

Company Quote

30.9
0.04 +0.13%
19 Sep 2014